With the introduction of PSMA PET ligands a decade ago, the landscape of prostate cancer (PC) management has shifted profoundly, and accordingly, the international and national guidelines have appreciated the added value of PSMA imaging through its implementation in routine clinical practice [1–5]. This evidence concerns the gene FOLH1 and prostate carcinoma.